Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label multicenter study of SHR-4610 alone and with SHR-A1811 in advanced solid tumors
CTR20254328Phase 2Active
- Sponsor
- Chengdu Shengdi
- Start
- Nov 2025
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-4610 in Nonhematologic neoplasms, sponsored by Chengdu Shengdi. Started Nov 2025; status: active.
02
Drugs
SHR-4610
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20254328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254328.